Hazard ratios (HRs) were adjusted for chemotherapy, trastuzumab, age at diagnosis, N-status, grade, pT-stage and ovarian ablation. Results: During follow-up, 237 recurrences and 182 deaths occurred.

Book Title: Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study
Author:
Published on 2018 by
ISBN: /
Total Page:
Book Category:
Book is About: Breast Cancer Treatment
Get Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study eBook


Get the Ebook

Abstract: Background: Prior randomised controlled trials on adjuvant hormonal therapy included HER2any patients; however, a differential effect of aromatase inhibitors (AIs) versus tamoxifen (TAM) may have been missed in ER+/HER2+ patients that comprise 7–15% of all breast cancer patients. In addition, a woman's hormonal microenvironment may influence sensitivity to TAM and AIs in the adjuvant setting, which changes during menopausal transition, a process that takes years. We studied the efficacy of AIs versus TAM in ER+/HER2+ breast cancer patients grouped by age at diagnosis as a proxy for menopausal status using treatment and outcome data from the nationwide population-based Netherlands Cancer Registry (NCR). Patients and methods: All women diagnosed between 2005 and 2007 with endocrine-treated, Tany Nany M0, ER+/HER2+ breast cancer were identified through the NCR ( n =1155). Patients were divided by age at diagnosis: premenopausal (≤45 years; n =326), perimenopausal (4555 years; n =525). A time-dependent variable, indicating whether AI or TAM was received for \u003e50% of endocrine treatment duration, was applied to subdivide groups by predominant treatment received. Recurrence-free survival (RFS) and overall survival (OS) were assessed using Kaplan–Meier survival estimation and Cox regression. Hazard ratios (HRs) were adjusted for chemotherapy, trastuzumab, age at diagnosis, N-status, grade, pT-stage and ovarian ablation. Results: During follow-up, 237 recurrences and 182 deaths occurred. Perimenopausal women derived significant RFS and OS benefit from AI compared with TAM, HR 0.47 (95% CI 0.25–0.91; P =0.03) and HR 0.37 (95% CI 0.18–0.79; P =0.01), respectively, whereas premenopausal women derived no benefit from AI compared with TAM. Treatment effects differed significantly between these age groups (interaction P =0.03 and P =0.02, respectively). Among postmenopausal women a small but non-significant AI benefit was observed. Conclusion: AI treatment, preferably without any TAM treatment, was associated with the best RFS and OS outcome in ER+/HER2+ perimenopausal breast cancer patients. Highlights: We studied all ER+/HER2+ Dutch breast cancer patients diagnosed between 2005 and 2007. Aromatase inhibitors (AIs) and tamoxifen (TAM) were compared in a time-dependent way. AIs not TAM significantly improve recurrence-free survival (RFS) and overall survival (OS) in perimenopausal women (45–55yearsat diagnosis). 5-year RFS benefit for AI compared with TAM (90% vs. 78%; adjusted HR 0.47; P =0.026). 5-year OS benefit for AI compared with TAM (96% vs. 87%; adjusted HR 0.37; P =0.010).

From the most popular Breast Cancer Treatment Books, Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study is the one of great book to have. You can get ebook from:

There are so many ebooks about Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study that are available to have. Thinking of having Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study ebook? You are in the right place. Get the ebook Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study by: .

Ebook entitled: Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study

Get the Ebooks

Book Details:
  1. Book was ranked at 33 by Google Books for Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study
  2. Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study published by since 2018 with ISBNs. The book ISBN 13 Code is and ISBN 10 Code is
  3. Reading Mode in Text Status is false and Reading Mode in Image Status is false
  4. The book has " Pages" is Printed at BOOK under Category
  5. Rated by Raters and have average rate at ""
  6. eBook Maturity (Adult Book) status is NOT_MATURE
  7. eBook written in en
  8. Book Preview Address: http://books.google.com/books?id=cG_KvQEACAAJ&dq=Breast+Cancer+Treatment&hl=&cd=352&source=gbs_api

Book Preview


Get Ebooks

The Button is not working? Try The Alternative links for "Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study by: ":